North America had the highest 12-month cancer prevalence rate in 2022. The 12-month prevalence rate for all cancers in North America as of this time was 595 per 100,000 population. This statistic displays 12-month cancer prevalence rates worldwide in 2022, by region.

Introduction

Cancer Statistics: Cancer continues to pose a major global health challenge, ranking among the top causes of mortality and disease burden worldwide. New cancer cases are rising steadily, influenced by factors such as an aging population, changing lifestyles, and environmental factors. Reliable and current cancer data are essential for comprehending the disease's scale, shaping public health strategies, optimizing resource distribution, and driving scientific research.

These statistics provide a comprehensive overview of recent global cancer incidence, mortality, and survival trends, emphasizing prominent cancer types and geographical differences. Through this analysis, policymakers and healthcare professionals can better focus efforts on prevention, early diagnosis, and treatment to lessen Cancer's impact on communities globally.

In 2022, there were around 20 million new cases of cancer worldwide. It is predicted that this number will increase to around 35.3 million incident cases in the year 2050. This statistic shows the predicted number of new cancer cases worldwide from 2022 to 2050.

Annual percent change and average annual percent change in age-standardized cancer incidence rates since 1984 to the most recent diagnosis year. The table includes a selection of commonly diagnosed invasive cancers, as well as in situ bladder cancer. Cases are defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3) from 1992 to the most recent data year and on the International Classification of Diseases, ninth revision (ICD-9) from 1984 to 1991.

Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

Users can access data about cancer statistics, specifically incidence and mortality worldwide for the 27 major types of cancer. Background Cancer Mondial is maintained by the Section of Cancer Information (CIN) of International Agency for Research on Cancer by the World Health Organization. Users can access CIN databases including GLOBOCAN, CI5(Cancer Incidence in Five Continents), WHO, ACCIS(Automated Childhood Cancer Information System), ECO (European Cancer Observatory), NORDCAN and Survcan. User functionality Users can access a variety of databases. CIN Databases: GLOBOCAN provides acces s to the most recent estimates (for 2008) of the incidence of 27 major cancers and mortality from 27 major cancers worldwide. CI5 (Cancer Incidence in Five Continents) provides access to detailed information on the incidence of cancer recorded by cancer registries (regional or national) worldwide. WHO presents long time series of selected cancer mortality recorded in selected countries of the world. Collaborative projects: ACCIS (Automated Childhood Cancer Information System) provides access to data on cancer incidence and survival of children collected by European cancer registries. ECO (European Cancer Observatory) provides access to the estimates (for 2008) of the incidence of, and mortality f rom 25 major cancers in the countries of the European Union (EU-27). NORDCAN presents up-to-date long time series of cancer incidence, mortality, prevalence and survival from 40 cancers recorded by the Nordic countries. SurvCan presents cancer survival data from cancer registries in low and middle income regions of the world. Data Notes Data is available in different formats depending on which type of data is accessed. Some data is available in table, PDF, and html formats. Detailed information about the data is available.

In 2022, there were an estimated 2.48 million new cases of trachea, bronchus, and lung cancer worldwide. Breast cancer was the second most common cancer type at that time with around 2.3 million new cases worldwide.

Number of new cancer cases

Cancer can be caused by internal factors like genetics and mutations, as well as external factors such as smoking and radiation. It occurs in the presence of uncontrolled growth and spread of abnormal cells. However, many cancer cases could be prevented, for example, by omitting cigarette usage and heavy alcohol consumption. Risk of developing cancer tends to increase with age and is most common in older adults. Nevertheless, cancer can develop in individuals of any age. Cancer can be treated through surgery, radiation, and chemotherapy, among other methods.

In the United States, there will be an estimated two million new cancer cases and 611,720 deaths in 2024. Among U.S. men, prostate cancer and lung and bronchus cancers are the most common cancer types as of 2024, totaling an estimated 299,010 and 116,310 cases, respectively. In women, breast cancer and lung and bronchus cancer are the most common newly diagnosed types, totaling 310,720 and 118,270 cases, respectively.

To investigate the global incidence of prostate cancer with special attention to the changing age structures. Data regarding the cancer incidence and population statistics were retrieved from the International Agency for Research on Cancer in World Health Organization. Eight developing and developed jurisdictions in Asia and the Western countries were selected for global comparison. Time series were constructed based on the cancer incidence rates from 1988 to 2007. The incidence rate of the population aged ≥ 65 was adjusted by the increasing proportion of elderly population, and was defined as the “aging-adjusted incidence rate”. Cancer incidence and population were then projected to 2030. The aging-adjusted incidence rates of prostate cancer in Asia (Hong Kong, Japan and China) and the developing Western countries (Costa Rica and Croatia) had increased progressively with time. In the developed Western countries (the United States, the United Kingdom and Sweden), we observed initial increases in the aging-adjusted incidence rates of prostate cancer, which then gradually plateaued and even decreased with time. Projections showed that the aging-adjusted incidence rates of prostate cancer in Asia and the developing Western countries were expected to increase in much larger extents than the developed Western countries.

The number of new cases, age-standardized rates and average age at diagnosis of cancers diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Cancer incidence rates are age-standardized using the direct method and the final 2011 Canadian postcensal population structure. Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

The file contains separate sheets that provide pertinent metadata for assessing the incidence and mortality rates of breast cancer based on various factors such as time, gender, region, country, and socio-demographic index (SDI). In addition to this information, the document also includes data on the World population age standard, the HDI of different countries in 1990, and Global Population Forecasts spanning from 2017 to 2100.

According to Cognitive Market Research, the global Cancer Diagnosis market size was USD 109614.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.50% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 43845.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 32884.35 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 25211.34 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 5480.73 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 2192.29 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
The consumables category is the fastest growing segment of the Cancer Diagnosis industry

Market Dynamics of Cancer Diagnosis Market

Key Drivers for Cancer Diagnosis Market

Increasing Rate of Cancer Diagnostics to Boost Market Growth

The rising global incidence of cancer, which affects millions of people a year, is a primary driver of the need for diagnostic testing. Numerous factors contribute to this tendency, such as the aging population, which increases the risk of developing some cancers in older adults. Changes in lifestyle, including poor eating habits, inactivity, and increased use of alcohol and tobacco, have also contributed to an increase in cancer incidence. Environmental factors, such as exposure to chemicals and hazardous compounds, exacerbate the problem and increase the risk of developing cancer. Therefore, as early detection and diagnosis are becoming more and more important to patients and healthcare professionals, effective cancer diagnostics are essential. The market for cancer diagnostics is expanding as a result of the increased emphasis on prompt and precise cancer detection, which highlights the value of novel diagnostic procedures. For Instance, in 2023, the Pan American Health Organization (PAHO) projects that there will be 20 million new cases and 10 million deaths, and by 2040, nearly 30 million cases will be reported annually.

Innovations in Diagnostic Technologies to Drive Market Growth

The market for cancer diagnostics is expanding as a result of advancements in diagnostic technologies that have greatly improved the precision and effectiveness of cancer detection. For example, non-invasive cancer biomarker identification in physiological fluids is made possible by liquid biopsies, which offer vital insights into tumor dynamics and therapy response. In a similar vein, molecular diagnostics has transformed the detection of particular genetic abnormalities and changes linked to different types of cancer, allowing for more individualized treatment strategies. High-resolution images of tumors are provided by advanced imaging methods like MRI and PET scans, which help with accurate staging and localization. Better patient outcomes result from these technical developments because they increase overall diagnosis accuracy and enable early intervention. The ongoing development of these cutting-edge diagnostic instruments is propelling market expansion and revolutionizing cancer treatment.

Restraint Factor for the Cancer Diagnosis Market

The High Price of Cutting-Edge Diagnostic Technology Will Limit Market Growth

The market for cancer diagnostics is severely hampered by the high price of sophisticated diagnostic tools. Advanced diagnostic instruments, such as molecular tests and imaging technologies, are frequently expensive, which limits healthcare facilities' access to them, especially in settings with limited resources. These institutions' capacity to provide thorough cancer screening and diagnostic services is restricted by this financial barrier, which eventually affects patient outcomes. These financial difficulties are further exacerbated by the costs associated with the development, research, and regulatory approval of new diagnostic instruments. Companies have to spend a lot of money to comply with...

Cuba CU: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 17.600 % in 2021. This records an increase from the previous number of 16.900 % for 2020. Cuba CU: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 17.050 % from Dec 2000 (Median) to 2021, with 22 observations. The data reached an all-time high of 18.300 % in 2001 and a record low of 16.200 % in 2012. Cuba CU: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Cuba – Table CU.World Bank.WDI: Social: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).;World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).;Weighted average;This is the Sustainable Development Goal indicator 3.4.1 [https://unstats.un.org/sdgs/metadata/].

BACKGROUND Comprehensive analyses of statistical data on breast cancer incidence, mortality, and associated risk factors are of great value for decision-making related to reducing the disease burden of breast cancer. METHODS: Based on data from the Annual Report of China Tumour Registry and the Global Burden of Disease (GBD), we conducted summary and trend analyses of incidence and mortality rates of breast cancer in Chinese women from 2014 to 2018 for urban and rural areas in the whole, eastern, central, and western parts of the country, and projected the incidence and mortality rates of breast cancer for 2019 in comparison with the GBD 2019 estimates. And the comparative risk assessment framework estimated risk factors contributing to breast cancer deaths and disability-adjusted life years (DALYs) from GBD. RESULTS: The Annual Report of the Chinese Tumour Registry showed that showed that the mortality rate of breast cancer declined and the incidence rate remained largely unchanged from 2014 to 2018. There was a significant increasing trend in incidence rates among urban and rural women in eastern China and rural women in central China, whereas there was a significant decreasing trend in mortality rates among rural women in China. The two data sources have some differences in their predictions of breast cancer in China in 2019. The GBD data estimated the age-standard DALYs rates of high body-mass index, high fasting plasma glucose and diet high in red meat, which are the top three risk factors attributable to breast cancer in Chinese women, to be 29.99/100,000, 13.66/100,000 and 13.44/100,000, respectively. Conclusion: The trend of breast cancer incidence and mortality rates shown in the Annual Report of China Tumour Registry indicates that China has achieved remarkable results in reducing the burden of breast cancer, but there is still a need to further improve breast cancer screening and early diagnosis and treatment, and to improve the system of primary prevention. The GBD database provides risk factors for breast cancer in the world, Asia, and China, and lays the foundation for research on effective measures to reduce the burden of breast cancer.

ObjectiveThis study evaluates global burden, disparities, and trends of female cancers (breast, cervical, uterine, ovarian) from 1990 to 2021, and identifies key contributing factors and intervention strategies.MethodsData from the Global Burden of Disease (GBD,1990–2021) Study and recent reports were analyzed to assess incidence, mortality, and disability-adjusted life years (DALYs) across 204 countries stratified by Socio-demographic Index (SDI). Regression and spatiotemporal analyses explored links with risk factors (e.g., obesity, HPV) and healthcare access.ResultsBreast cancer dominated the burden, with age-standardized incidence rates (ASIR) rising by 28% (2.08 million new cases in 2021), driven by lifestyle factors (high BMI, alcohol use) and showing a strong connection with higher SDI (r=0.82). Cervical cancer remained a critical challenge in low- and middle-income regions, showing a strong negative correlation with SDI(r = -0.75), though Age-Standardized Mortality Rate (ASMR) declined globally (-1.4% annual change). Uterine cancer incidence rose steadily (0.7% annual increase; 473,614 cases in 2021), primarily attributable to obesity, while ovarian cancer mortality remained high (207,000 deaths) due to late diagnosis. Key modifiable risks included HPV infection (85% of cervical cancers), tobacco use, and reproductive behaviors.ConclusionThe global burden of female cancers presents a significant public health challenge. Disparities in female cancer burden reflect inequities in healthcare access and rising metabolic risks. Priority actions include HPV vaccination, low-cost screening, and obesity control. Equity-focused, data-informed policies are crucial to reduce global disparities.

In 2022, Australia had the fourth-highest total number of skin cancer cases worldwide and the highest age-standardized rate, with roughly 37 cases of skin cancer per 100,000 population. The graph illustrates the rate of skin cancer in the countries with the highest skin cancer rates worldwide in 2022.

Simulation results (means and 95% uncertainty intervals) for: Ward ZJ, Yeh JM, Bhakta N, Frazier AL, Atun R. Estimating the total incidence of global childhood cancer: a simulation-based analysis. Lancet Oncol 2019; 20(4): 483-493.

cancer therapeutics and biotherapeutics Market Outlook

According to our latest research, the global cancer therapeutics and biotherapeutics market size stood at USD 195.8 billion in 2024, reflecting robust demand and innovation in oncology treatments. The market is projected to expand at a CAGR of 8.7% from 2025 to 2033, reaching an estimated USD 418.7 billion by 2033. This impressive growth is driven by the increasing incidence of cancer worldwide, rapid advancements in biotherapeutic modalities, and the ongoing introduction of novel, targeted therapies that enhance patient outcomes.

A key growth factor for the cancer therapeutics and biotherapeutics market is the rising global cancer burden. According to the World Health Organization, cancer remains one of the leading causes of morbidity and mortality worldwide, with over 20 million new cases and 10 million deaths in 2024. The aging population, lifestyle changes, environmental factors, and improved diagnostic capabilities are contributing to the escalating prevalence of various cancer types. This has led to a heightened demand for innovative and effective therapeutic solutions, spurring investments in research and development by both public and private entities. In particular, the emergence of precision medicine and personalized therapies has revolutionized cancer care, offering hope for improved survival rates and quality of life for patients.

Another significant driver is the rapid advancement and adoption of biotherapeutics, such as monoclonal antibodies, immune checkpoint inhibitors, and cell therapies. These modalities have demonstrated superior efficacy and safety profiles compared to traditional chemotherapies, leading to their widespread adoption in clinical practice. Pharmaceutical and biotechnology companies are increasingly focusing on the development of next-generation biotherapeutics, leveraging cutting-edge technologies like CRISPR, CAR-T, and bispecific antibodies. The expanding pipeline of innovative drugs, coupled with expedited regulatory approvals and favorable reimbursement policies in key markets, is accelerating the commercialization of novel cancer therapies and broadening patient access to life-saving treatments.

Furthermore, the integration of artificial intelligence, big data analytics, and digital health tools is transforming the landscape of cancer therapeutics and biotherapeutics. These technologies are enabling more accurate tumor profiling, better patient stratification, and optimized treatment regimens, ultimately leading to improved clinical outcomes. Collaborations between academic institutions, research organizations, and industry stakeholders are fostering a vibrant ecosystem for oncology innovation. Additionally, growing awareness among patients and healthcare providers about the benefits of targeted and immunotherapeutic approaches is driving uptake and supporting market expansion. The convergence of scientific breakthroughs, supportive policy frameworks, and patient-centric care models is expected to sustain the robust growth trajectory of the cancer therapeutics and biotherapeutics market over the forecast period.

Regionally, North America remains the dominant market, accounting for the largest share in 2024, followed by Europe and Asia Pacific. The United States, in particular, benefits from a well-established healthcare infrastructure, strong R&D capabilities, and high healthcare expenditure. However, the Asia Pacific region is witnessing the fastest growth, fueled by rising cancer incidence, increasing healthcare investments, and expanding access to advanced therapies in countries like China, Japan, and India. Europe continues to play a pivotal role, driven by supportive regulatory environments and active participation in global oncology research initiatives. Latin America and the Middle East & Africa are gradually emerging as promising markets, supported by improving healthcare access and growing awareness about cancer therapies.

Product Type Analysis

The cancer therapeutics and biother

India IN: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data was reported at 19.800 NA in 2016. This records a decrease from the previous number of 20.000 NA for 2015. India IN: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data is updated yearly, averaging 21.200 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 23.400 NA in 2000 and a record low of 19.800 NA in 2016. India IN: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s India – Table IN.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

Liberia LR: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 17.600 % in 2016. This records an increase from the previous number of 17.200 % for 2015. Liberia LR: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 18.000 % from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 19.000 % in 2005 and a record low of 17.200 % in 2015. Liberia LR: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Liberia – Table LR.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

Global Breast Cancer Screening (Programme Data) by Country, 2023 Discover more data with ReportLinker!